Loading
A phase 1/2 trial of Elironrasib, Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06128551 by Revolution Medicines, Inc., with 534 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-12. Interventions recorded: Elironrasib, Daraxonrasib. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Pancreatic ductal adenocarcinoma.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.